Anzeige
Mehr »
Sonntag, 07.06.2026 - Börsentäglich über 12.000 News
Breaking News: Nasdaq Quantencomputer Play mit riesigem Kurspotential!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40FCQ | ISIN: US87961M1053 | Ticker-Symbol: T3X0
Siehe auch TELIX PHARMACEUTICALS LIMITED
Frankfurt
05.06.26 | 09:08
8,050 Euro
+5,23 % +0,400
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
TELIX PHARMACEUTICALS LIMITED ADR Chart 1 Jahr
5-Tage-Chart
TELIX PHARMACEUTICALS LIMITED ADR 5-Tage-Chart

Aktuelle News zur TELIX PHARMACEUTICALS LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TELIX PHARMACEUTICALS LIMITED ADR Aktie jetzt für 0€ handeln
DiTelix, United Imaging partner on theranostics research in U.S.6
DiTelix Pharmaceuticals Limited: Telix and United Imaging Announce Strategic Theranostics Collaboration311Partnership to evaluate Telix's innovative precision medicine products and candidates in combination with United Imaging's advanced scanner platforms.Initial focus on TLX101-Px (Pixclara®1, Floretyrosine...
► Artikel lesen
MoTelix Pharmaceuticals Limited: ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 202614
MoTELIX PHARMACEUTICALS LIMITED: Notification regarding unquoted securities - TLX3
MoTELIX PHARMACEUTICALS LIMITED: Appendix 3Y Change in Director Interest - C Behrenbruch12
MoTELIX PHARMACEUTICALS LIMITED: Appendix 3Y Change in Director Interest - M McDonald1
MoTELIX PHARMACEUTICALS LIMITED: Appendix 3Y Change in Director Interest - W Jellison2
MoTELIX PHARMACEUTICALS LIMITED: Appendix 3Y Change in Director Interest - Maria Rivas2
MoTELIX PHARMACEUTICALS LIMITED: Appendix 3Y Change in Director Interest - David Gill7
26.05.TELIX PHARMACEUTICALS LIMITED: Becoming a substantial holder9
26.05.What does a takeover in the US tell us about the value of Telix shares?27
21.05.Telix Pharmaceuticals Ltd - 6-K, Report of foreign issuer19
21.05.TELIX PHARMACEUTICALS LIMITED: Results of Annual General Meeting11
21.05.TELIX PHARMACEUTICALS LIMITED: Telix Annual General Meeting Presentation24
21.05.TELIX PHARMACEUTICALS LIMITED: Telix Annual General Meeting Chairman and CEO Addresses7
18.05.Telix schließt Patientenrekrutierung für Glioblastom-Therapiestudie ab13
18.05.Telix completes enrollment in glioblastoma therapy trial6
18.05.Telix Pharmaceuticals Limited: IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing165IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.Maximum dose reached with no dose-limiting toxicities observed.TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT...
► Artikel lesen
15.05.Telix to Explore PSMA-PET Imaging in Collaborations with EDAP TMS and Profound9
15.05.Profound Medical Corp (2): Profound, Telix form partnership on prostate imaging4
Weiter >>
249 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1